Table 3.
Patients included in analysis of biopsies at ≥1 yr (Nantes Center)a
| Parameter | Group
|
||||
|---|---|---|---|---|---|
| Normal | CNI Tox | IF/TA | TG (C4d−, Anti-HLA−) | TG (C4d+, Anti-HLA+; Chronic AMR) | |
| n | 7 | 7 | 9 | 11 | 18 |
| Recipient age (yr; median [range]) | 35 (18 to 61) | 47 (29 to 56) | 53 (24 to 56) | 62 (45 to 75) | 47 (24 to 71) |
| Gender ratio (M:F) | 6:1 | 4:3 | 4:5 | 4:7 | 10:9 |
| Donor age (yr; median [range]) | 34 (12 to 74) | 40 (16 to 48) | 48 (23 to 64) | 57 (8 to 65) | 35 (14 to 75) |
| Time after transplantation (yr; median [range]) | 1 (1-yr protocol biopsies) | 5 (1 to 11) | 2 (1 to 22) | 4 (1 to 14) | 9 (1 to 18) |
| HLA incompatibilities (mean ± SD) | 2.8 ± 1.7 | 2.7 ± 1.9 | 2.8 ± 1.2 | 4.3 ± 1.4 | 3.0 ± 1.6 |
| % First transplantationsb | 100 | 57 | 100 | 91 | 68 |
| Cockroft creatinine clearance (ml/min; mean ± SD) | 75.6 ± 17.6 | 57.1 ± 31.9 | 56.8 ± 16.3 | 28.2 ± 17.3 | 29.1 ± 16.6 |
| Proteinuria (g/24 h; median [range]) | 0.12 (0.05 to 0.43) | 1.22 (0.14 to 4.47)c | 0.14 (0.01 to 6.37) | 1.00 (0.89 to 5.92) | 1.88 (0.80 to 3.17) |
| C4d+ biopsy | 0/7 | 0/7 | 0/9 | 0/11 | 18/18 |
| Banff c grade (mean ± SD) | 0.0 ± 0.0 | 1.7 ± 0.8 | 1.3 ± 0.7 | 1.4 ± 0.7 | 2.1 ± 0.9 |
| Immunosuppression protocol | Antimetabolite: Aza (0/7), MMF (6/7) CNI: CsA (0/7), FK 506 (6/7)Rapamycin (0/7)Steroids (1/7) | Antimetabolite: Aza (2/7), MMF (4/7) CNI: CsA (4/7), FK 506 (3/7)Rapamycin (0/7)Steroids (3/7) | Antimetabolite: Aza (2/9), MMF (6/9) CNI: CsA (1/9), FK 506 (4/9)Rapamycin (3/9)Steroids (4/9) | Antimetabolite: Aza (0/11), MMF (11/11) CNI: CsA (2/11), FK 506 (8/11)Rapamycin (1/11)Steroids (2/11) | Antimetabolite: Aza (2/18), MMF (9/18) CNI: CsA (8/18), FK 506 (6/18)Rapamycin (0/18)Steroids (4/18) |
a
Aza, azathioprine.
b
All but one were from deceased donors.
c
One patient had a proteinuria of 4.47 g/24 h at the time of biopsy, probably because of hyperfiltration (as a result of obesity [BMI >40]).